Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE,CONFIRM,and ENDORSE”

Gold R, Arnold DL, Bar-Or A et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ followup of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord 2020; 13: 1–17. doi: 10.1177/1756286420915005

In the above referenced article, in Figure 1 the number of patients in the PBO/DMF and DMF/DMF efficacy populations were reported incorrectly as n=501 and n=249, respectively. In fact, the n number for the PBO/DMF cohort should be n=249, and for DMF/DMF should be n=501. Figure 1 has been changed to reflect as given below:

Figure 1.

Patient populations for safety, efficacy, and lymphocyte analysis.